Lipoprotein(a) ning yurak-qon tomir kasalliklarining rivojlanishidagi ahamiyati

Tikhonov AV. Lp(a) lipoprotein and atherosclerosis. Ateroskleroz. 2007;3(1):3–16. In Russian: Тихонов А.В.Лп(а) липопротеид и атеросклероз // Атеросклероз 2007,Т3,№1,3-16.

Zueva IB, Baratashvili GG, Krivonosov DS, Buch AV, Sidorkevich SV. Lipoprotein(a) as a cardiovascular risk factor. Current state of the problem. Vestnik Rossiyskoy Voenno-Meditsinskoy Akademii. 2017;1(57):219–25. In Russian: Зуева И.Б.,Бараташвили Г.Г.,Кривоносов Д.С,Буч А.В.,Сидоркевич С.В.//Липопротеин(а) как фактор сердечно-сосудистого риска.Современное состояние пробле- мы.Вестник российской военно-медицинской академии.2017;1(57):219-225.

Anping Cai,Liwen Li,Zhang Y.Lipiprotein(a):a promising marker for residual cardiovascular risk assessment.Dis Markers.2013;35(5):551-559.

Fruchart J.C.,Sacks F.M.,Hermans M.P. The residual risk reduction initiative:а call to action to Reduce residual risk in dyslipideamic patients.Diab Vasc res.2010;2:319-335.

Polyakova EA, Khalimov YuSh, Bazhenova EA, Bakher TM. Lipoprotein(a), atherosclerosis and cardiovascular risk. Ratsionalnaya Farmakoterapiya v Kardiologii. 2024;20(5):559–65. In Russian: Полякова Е.А.,Халимов Ю.Ш.,Баженова Е.А.,Бахер Т.М.//Липопротеин(а),атеросклероз и сердечно- сосудистый риск.Рациональная фармакотерапия в кардиологи 2024;20(5);559-565.

Afanasyeva OI, Pokrovskiy SN. Lipoprotein(a) – an underestimated cardiovascular risk factor in Russia. Time to implement in clinical practice. Rossiyskiy Kardiologicheskiy Zhurnal. 2024;29(8):6035:8–13. In Russian: Афанасьева О.И.,Покровский С.Н.//Липопротеид(а)-недооцененный в России фактор риска сердечно-сосудистых заболеваний.Время внедрять в клиническую практику.Российский кардиологический журнал 2024;29(8):6035;8-13.

Berg K.A. A new serum type system in man-the Lp system.Acta pathol Microbiol Scand 1963;59:369-82. https://doi.org/10.1111/j.1699-0463.1963.tb01808.x.

Schmidt K. et al. Structure,function and genetics of lipoprotein(a)//Journal of lipid research.-2016.-T.57.-№8.-C.1339-1359.

Kaschinsky M,Marcovina SM.//Lipoprotein(a).In:C.Ballantyne,ed.Clinical lipidology:a companion to Braunwalds heart disease.Philadelphia:Saunders Elsevier,2019.P.130-143/

Tsioulos G.et al.Lipoprotein(a) and atherosclerotic cardiovascular disease:where do we stand?//Int.J.Mol.Sci.-2024-V25-№6 P3537/ https://doi.org/10.1093/clinchem/41.2.246.

Marcovina S.M. et al.Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)//Clin.Chem.-1995.-V.41. №2.-P246-255/https://doi.org/10.1093/clinchem/ 41.2.246/.

Kronenberg F,Mora S,Stroes ESG,et al.Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of European Atherosclerosis Society.// Atherosclerosis.2023;374:107-20.https: //doi.org/10.1016/j/atherosclerosis.2023.04.012.

Kronenberg F,Utermann G. Lipoprotein(a):Resurrected by genetics.J.Intern.Med 2013;273 (1):6-30. https://doi.org/10.1111/j.1365-2796.2012.02592.x.

Iannuzzo G et al./ Lipoprotein(a) where do we stand? Fron the Physiopathology to Innovative therapy/Biomedicines-2021-V.9;№7.P838.https://doi.org/10.3390/biomedicines9070838.

Ward N.C. Molecular,population,and clinical aspects of lipoprotein(a): a bridge too far?//Journal of clinical medicine-2019-№7(12)-P1-23.

[16] Hegele R.,Lalouel J.Lp(a) and plasminogen:linkage analysis//9-th Intern.Congr.in fibrinolysis,USA,11,9,1988,From Sunlev Res.,Chicago,1989-p.208.

Tsygankova O.V. and others.The clinical and pathophysiological role of lipoprotein(a) in the development of atherosclerosis-associated diseases//Breast cancer.-2020.-T28,No.12.-pp.4-8. In Russian: Цыганкова О.В. и др.Клиническая и патофизиологическая роль липопротеина(а) в развитии атеросклероз-ассоцированных заболеваний//РМЖ.-2020.-Т28,№12.-С.4-8.

Koschinsky ML.Novel insights into Lp(a) Physiology and Pathogenesity:more questions than answers?/Cardiovascular hematol. Disord.drug targets.2006;6(4):267-284.

Jawi M.M.,et al.Lipoprotein(a) the insurgent: a new insight into the structure,function,metabolism,pathogenisity,and medications affecting lipoprotein(a) molecule//Lipids.- 2020-V2020.-26p.https://doi.org/10.1155/2020/3491764.

w Graham M.J.,Viney.,Crooke R.M.,Tsimikas S. Antisense inhibition of apolipoprotein(a) to lower plasma lipoprotein(a) levels in humans.J.lipid res.2016;57(3):340-351.

Marcovina S.M., Koschinsky M.I., Albers J.J.,Skarlatos S. report of the National Heart,lung,and blood institute workshop on lipoprotein(a) and cardiovascular disease:recent advanced and future directions.clinical chemistry.2003;49(11);1785-1796.

Ezhov MV, Safarova MS, Malchin YuG, Soboleva DI, Afanasyeva OI, Pokrovskiy SN. Association of elevated lipoprotein(a) levels with coronary artery patency during the first year after percutaneous coronary interventions. Klinitsist. 2011;1:18–24. In Russian: Ежов М.В.,Сафарова М.С.,Мальчин Ю.Г.,Соболева Д.И.,Афанасьева О.И.,Покровский C.Н.Связь высокого уровня липопротеина(а) с проходимостью коронарных артерий в течение первого года после чрескожных коронарных вмешательств.Клиницист.2011;1:18-24.

Erqou S.,Kaptoge S.,Perry L.L.,Di Angelantonio E.,Thompson A.,White I.R. et al.Lipiprotein(a) concentration and risk of coronary heart disease,stroke and non-vascular mortality.Emerging risk factors collaboration.J Am Med Assoc.2009;302(4):412-423.

Bennet A.,Di A.E.,Erqou S.,Eiriksdottir G.,Sigurdsson G.,Woodward M. et al.Lipoprotein(a) levels and risk of future coronary heart disease:large-scale prospective data.Arch Intern Med/2018;168(6):598-608.

Kamstrup P.R.,Tybjaerg-Hansen A.,Nordestgard B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.J Am coll. Cardiol.2014;63(5):470-477.

Manikpurage HD,Paulin A,Girard A, et al.Contribution of lipoprotein(a) to polygenic risk prediction of coronary artery disease:a prospective UK biobank analysis.Circ.genom precis med/2023;6(5):470-7. https://doi.org/10.1161/CIRCGEN.123.004137.

Ezhov MV, Safarova MS, Afanasyeva OI, Ilyina LN, Lyakishev AA, Pokrovskiy SN. Lipoprotein(a) as a predictor of poor long-term outcome after coronary artery bypass grafting. Kardiologiya. 2011;51(1):18–22. Russian. In Russian: Ежов М.В.,Сафарова м.С.,Афанасьева О.И.,Ильина Л.Н.,Лякишев А.А.,Покровский С.Н. Липопротеин(а) как предиктор неблагоприятного прогноза в отдаленные сроки после операции коронарного шунтирования.Кардиология.2011;51(1):18-22.

Desmarais RL.,Sarembock IJ.,Ayers CR.,Vernon SM.,Powers ER.,Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after balloon angioplasty.Circulation.1995;91(5):1403- 1409.

Alieva RB, Shek AB, Abdullaeva AA, Fozilov KhG, Khoshimov ShU, Abdullaeva GD, Zakirova D, Kan LE, Kim AR, Kurbanova RA, Yusupalieva DB. Sex differences in 5-year risk of major cardiovascular events in patients with ischemic heart disease and elevated lipoprotein(a) levels. Rossiyskiy Kardiologicheskiy Zhurnal. 2025;30(3):6019. https://doi.org/10.15829/1560-4071-2025-6019. In Russian: Алиева Р.Б.,Шек А.Б.,Абдуллаева А.А.,Фозилов Х.Г.,Хошимов Ш.У.,Абдуллаева Г.Д.,Закирова Д., Кан Л.Э.,Ким А.Р.,Курбанова Р.А.,Юсупалиева Д.Б. Половые различия в 5-летнем рис- ке больших сердечно-сосудистых событий у больных ишемической болезнью сердца и повы- шенным уровнем липопротеида(а).Российский кардиологический журнал 2025;30(3):6019. https://doi.org/10.15829/1560-4071-2025-6019.

Kronenberg F,Mora S,Stroes ESC,et al.Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis:a European atherosclerosis society consensus statement//Eur.heart J.2022.oct 14;43(39):3925-46. https://doi.org/10.1093/eurheartj/ehac361.

Velkov VV. Lipoprotein(a): new perspectives for laboratory diagnostics. Kliniko-Laboratorny Konsilium. 2012;(4):37–48. In Russian: Вельков В.В. Липопротеин(а):новые перспективы для лабораторной диагностики/В.В.Бельков//Клинико-лабораторный консилиум-2012.-№4(44).С.37-48.

Ezhov MV, et al. Lipid metabolism disorders. Clinical guidelines–2023. Rossiyskiy Kardiologicheskiy Zhurnal. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471. In Russian: Ежов М.В. и др. Нарушение липидного обмена.Клинические рекомендации-2023//Российский кардиологический журнал.-2023.-Т.28.№5.С.5471.https://doi.org/10.15829/1560-4071-2023-5471.

Mach F. et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk//Eur.Heart J.-2020.-V.41.-№1.P.111-188.https://doi.org/10/1093/eurheartj/ehj455.

Grundy SM, Stone NJ, Bailey AL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol:a report of the American college of cardiology/American heart association task force on clinical practice guidelines.Circulation.2019;139(25):е1082е1143.https://doi.org/10.1061/j.jacc.2018.11.002.

Kalacheva OS, Vershinina MG, Konovalov GA, Stereopola NA. Lipoprotein(a) as an independent risk factor for cardiovascular events: the role of laboratory diagnostics. Kremlevskaya Meditsina. Klinicheskiy Vestnik. 2024;(3):48–56. https://doi.org/10.48612/cgma/1r41-a9hb-8d11. In Russian: Калачева О.С.,Вершинина М.Г.,Коновалов Г.А.,Стериопола Н.А. Липопротеин(а)-независимый фактор риска сердечно-сосудистых событий.Значение лабораторной диагностики.Кремлевская медицина.Клинический вестник.2024.№3 С.48-56. https://doi.org/10.48612/cgma/1r41-a9hb-8d11.